The market for ischemia-reperfusion injury therapeutics is anticipated to expand at a CAGR of 6.2% during the forecast period of 2024 to 2032. Reperfusion injury, also known as Ischemia-Reperfusion Injury, is the tissue damage that occurs when blood supply returns to ischemic tissue. Increased tissue damage and fluid filtration across the tissue are the primary factors driving the market's expansion.
The electronic health records (EHR) market has emerged as a transformative force in the healthcare industry, reshaping the way patient information is managed and leveraged. The EHR market is expected to grow at a CAGR of 4.5% during the forecast period of 2024 to 2032. The electronic health records market is expected to continue its transformative impact on healthcare, driven by factors such as enhanced clinical decision-making, regulatory initiatives and incentives, and cost reduction and efficiency gains.
The anti-infective drugs market is expected to witness a CAGR of 3.8% during the forecast period of 2024 to 2032, driven by various factors. Anti-infective drugs, also known as antimicrobial drugs, are used to treat infectious diseases caused by bacteria, viruses, fungi, and parasites. These drugs play a crucial role in combating infections and reducing morbidity and mortality rates associated with infectious diseases. This analysis provides a brief overview of the anti-infective drugs market, followed by an in-depth examination of the three key drivers and one restraint impacting the market.
Plasma Protein Therapeutics Market Is Projected to Expand At A CAGR Of 6.5% Between 2023 And 2031. A variety of life-threatening & chronic disorders such as hematological diseases, immune deficiencies, genetic diseases, neurological disorders among others are treated with plasma proteins. The different clinical responses of plasma proteins are due to its unique biochemical profile, and variances in production & processing technologies. Recent developments observed in plasma protein therapeutics industry are satisfactory and ground breaking, especially recently approved recombinant protein therapeutics which caters several clinical indications such as autoimmune diseases, cancers, infectious diseases and genetic disorders.
Nutraceutical is a combined term for nutrition and pharmaceutical products that claim to exhibit immense health benefits. Considerable interest for nutraceuticals grew due to the bioactive components of nutraceuticals that have additive nutritional value to human health. Increasing economies of developing nations along with countries with emerging economies is expected to expand the nutraceuticals industry.
osteoporosis is a common disease characterized by porous bone structure, lower bone mass and reduced bone strength. Osteoporosis is a condition where the regrowth of bone is slower than the breakage of bone. It is estimated that worldwide around 200 million population are affected with osteoporosis and it causes around 9 million fractures annually which is a major public concern as the estimated cost of osteoporosis is about 19 billion in United States only.
Mouth Ulcers Treatment Market Expected to Grow at 3.5% by 2031, mouth ulcers are painful sores that can be developed in mucous membrane of oral cavity or at the underneath of gums and restricts individual’s ability to chew, bite or eat. Depending on the size, shape and number the mouth ulcer can be classified as minor ulcer (2-8 mm diameter), major ulcer (bigger and uneven edges) and herpetiform ulcer (bunch of smaller injuries with irregular shapes). The principle causes of mouth ulcer are viral or bacterial infection, drug reaction, tooth decay, dentures, mechanical trauma, emotional stress, nutrients deficiency, changes in hormonal level and food allergy.
The report titled “Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market - Growth, Future Prospects, and Competitive Analysis, 2023 – 2032” offers strategic insights into the overall ABSSSI treatment market along with the market size and estimates for the duration 2020 to 2032. The said research study cover in-depth analysis of multiple market segments based on type of infection, pathogen, drug, and different geographies.
Rheumatoid arthritis is an autoimmune, inflammatory disease that causes chronic pain, swelling and loss in the functioning ability of joints. It occurs when the immune system attacks the synovium – the inner lining of membranes that surrounds the joints. In some patients, the antibodies also damage some body systems including the skin, heart, eyes, lungs and blood vessels. Prevalence of rheumatoid arthritis widely varies in different geographic region, the lowest rates is observed in the Asian countries and higher rates among some American populations.
Fabry disease is a rare, X-linked inherited, disorder of lipid metabolism resulting from the deficient activity of the enzyme, alpha-galactosidase-A. This enzyme normally responsible for the breakdown of globotriaosylceramide, results in abnormal deposits of a particular fatty substance in walls of the blood vessel throughout the body. Characteristic features of Fabry disease include episodes of pain, cloudiness of the front part of the eye, clusters of small and dark red spots on the skin, hearing loss also involves life-threatening complications such as heart attack, kidney damage and stroke.
The drugs by therapeutic area include therapy for oncology, cardiovascular, central nervous system, infectious diseases, respiratory, and others. The therapeutic area represents the specific area of medicine where the drug is intended to be used, based on its mechanism of action and intended clinical use. One of the primary drivers of the drugs by therapeutic area market is the increasing prevalence of diseases worldwide. Chronic diseases such as cancer, cardiovascular diseases, and neurological disorders are a significant burden on healthcare systems globally. There is an urgent need for new and effective therapies to treat these diseases, which has led to the growth of the drugs in the therapeutic area market.
The revenues generated by the drugs in the therapeutic area market have been consistently high over the years. The global pharmaceutical market is expected to reach USD 1.5 trillion by 2023, with oncology being the leading therapeutic area. The increasing demand for new therapies, coupled with advancements in technology and an increasing focus on personalized medicine, is expected to drive the growth of the market in the coming years. One of the emerging trends in the drugs by therapeutic area market is the increasing use of precision medicine. Precision medicine involves tailoring medical treatments to individual patients based on their unique genetic and molecular profiles. The development of precision medicine requires the use of advanced diagnostic tools and drug discovery technologies, which have contributed to the growth of drugs in the therapeutic area market.
Another trend in the drugs by therapeutic area market is the increasing focus on biologics. Biologics are drugs that are produced from living cells and are used to treat a wide range of diseases, including cancer and autoimmune disorders. Biologics are more complex than traditional small-molecule drugs, and their development requires specialized manufacturing processes and clinical trial design. The increasing demand for biologics has contributed to the growth of the drugs by therapeutic area market. The increasing focus on rare diseases is also driving the growth of the drugs by therapeutic area market. Rare diseases are defined as diseases that affect fewer than 200,000 people in the United States. Although each rare disease affects a small number of people, there are over 7,000 rare diseases, which together affect millions of people worldwide. There is an urgent need for new therapies to treat rare diseases, which has led to the growth of drugs in the therapeutic area market.
The increasing use of combination therapies is driving the growth of the drugs by therapeutic area market. Combination therapies involve the use of two or more drugs to treat a disease. Combination therapies can improve patient outcomes by targeting multiple pathways involved in the disease process. The development of combination therapies requires the use of advanced drug discovery technologies and clinical trial design, which has contributed to the growth of the drugs by therapeutic area market. The increasing prevalence of diseases worldwide, advancements in technology, and the emerging trends in precision medicine, biologics, rare diseases, and combination therapies are expected to drive the growth of the drugs by therapeutic area market.
